RxDoctor Payments Data

Vitaliy Shaulov, MD

Psychiatry · Laguna Hills, CANPI 1699705590

Payments from drug & device makers

$12,418in general payments, 2019–2025

Across 686 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Vanda Pharmaceuticals Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$865
  • Supernus Pharmaceuticals, Inc.$817
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$757
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$12,411100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,418 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$103,519
Medicare patients
133
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AtivanLorazepam11$87,536
RexultiBrexpiprazole38$57,589
TrintellixVortioxetine Hydrobromide47$28,489
BelsomraSuvorexant25$10,901
Dextroamphetamine Sulfate26$7,278
Ambien CrZolpidem Tartrate12$7,051
VyvanseLisdexamfetamine Dimesylate14$6,357
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine38$2,952
Temazepam44$2,334
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine79$2,328
Lamotrigine202$2,095
Bupropion XlBupropion Hcl66$1,892
Aripiprazole45$1,642
Paliperidone ErPaliperidone17$1,532
Divalproex Sodium ErDivalproex Sodium40$1,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,514$57,58938 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$865$34,84661 claims
MerckBelsomra$243$10,90125 claims
Almatica Pharma LLCSertraline Hcl$155$23014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →